Non-therapeutic, non-food preparations comprising dihydromyricetin

Incorporating specific stereoisomers of dihydromyricetin into cosmetic preparations enhances potency and stability, addressing degradation issues and reducing unwanted changes in cosmetic formulations.

WO2026234290A1PCT designated stage Publication Date: 2026-11-12DSM IP ASSETS BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063541
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-11
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Dihydromyricetin is prone to undesired degradation under heat, oxygen, and heavy metals, leading to unpleasant odor and color changes in cosmetic formulations, and existing stereoisomers do not effectively address these issues in cosmetic applications.

Method used

Incorporating specific stereoisomers of dihydromyricetin, such as (2S,3S)-, (2R,3S)-, and (2S,3R)-dihydromyricetin, into cosmetic preparations to enhance potency and stability, thereby allowing for lower dosages and reduced degradation.

Benefits of technology

The use of these stereoisomers increases potency and reduces degradation symptoms, enabling lower dosages and minimizing odor and color changes in cosmetic products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000009_0001
    Figure IMGF000009_0001
  • Figure IMGF000009_0002
    Figure IMGF000009_0002
  • Figure IMGF000010_0001
    Figure IMGF000010_0001
Patent Text Reader

Abstract

A method of application of one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin to a keratinous material, preferably skin and / or hair and a non-therapeutic, non-food preparation, preferably a cosmetic preparation, comprising one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] NON-THERAPEUTIC, NON-FOOD PREPARATIONS COMPRISING DIHYDROMYRICETIN

[0002] TECHNICAL FIELD OF THE INVENTION

[0003]

[0001] The present invention relates to non-therapeutic, non-food preparations comprising dihydromyricetin, in particular cosmetic preparations comprising dihydromyricetin, the compounds within such preparations, the use of such compounds and preparations and a method of application thereof.

[0004] BACKGROUND OF THE INVENTION

[0005]

[0002] Dihydromyricetin (DHM), also sometimes referred to as ampelopsin, is a flavonoid compound found for example in the plant species Hovenia dulcis and Ampelopsis grossedentata. Dihydromyricetin is a known and valuable cosmetic ingredient.

[0006]

[0003] For example, FR2868701 describes certain dihydroflavonols for the preparation of a cosmetic and I or pharmaceutical composition for the treatment of cellulite. In passing, dihydromyricetin is mentioned as an example of such dihydroflavonols.

[0007]

[0004] DE102009055916 describes the use of dihydromyricetin for the preparation of cosmetic or dermatological preparations for increasing dermal collagen synthesis and for the treatment and prophylaxis of the symptoms of intrinsic and I or extrinsic skin aging. The dihydromyricetin is indicated to be so-called (+) dihydromyricetin, stipulated as (2R, 3R) -3,5,7-trihydroxy-2- (3,4,5-trihydroxyphenyl) chroman-4-one).

[0008]

[0005] DE102020213959 describes the use of dihydromyricetin as an epigenetic active substance for cosmetic or dermatological skin care. In this context, the substance dihydromyricetin was mentioned to show an inhibitory effect on DNA methyltransferase 1 ((DNMT1). Also here, the dihydromyricetin is indicated to be so-called (+) dihydromyricetin, stipulated as (2R, 3R) -3,5,7-trihydroxy-2- (3,4,5-trihydroxyphenyl) chroman-4-one).

[0009]

[0006] Unfortunately dihydromyricetin shows undesired degradation under the influence of heat, oxygen and heavy metals that may lead to unpleasant odor- and color changes of a formulation.

[0010]

[0007] For example, Zhang et al, in their article titled “A multifaceted review on dihydromyricetin resources, extraction, bioavailability, biotransformation, bioactivities,and food applications with future perspectives to maximize its value", published in eFood Vol. 2(4); August (2021), pages 164-184, explain that (+)dihydromyricetin is very sensitive to temperature and that also certain metal ions accelerated degradation of dihydromyricetin.

[0011]

[0008] Zhang et al. mention that dihydromyricetin can exist in 4 theoretical stereoisomers, namely (2R,3R)-dihydromyricetin (also referred to as (+) dihydromyricetin); (2S,3S)-dihydromyricetin (also referred to as (-) dihydromyricetin); (2R,3S)-dihydromyricetin which according to Zhang is little-known; and (2S,3R)-dihydromyricetin which according to Zhang is unreported. Zhang et al. consider the (2R, 3R)-configuration as the default form and it is stated that different stereoisomers appear to exhibit distinct activities and pharmacokinetic characteristics creating the need to determine the accurate configuration of dihydromyricetin in bioassays.

[0012]

[0009] Umair et al, in their article titled “Chirality of the biomolecules enhanced its stereospecific action of dihydromyricetin enantiomers" , published in Food Science & Nutrition, 2020, pages 4843-4855 and Wang et al, in their article titled “Solid-state characterization of optically pure (+)Dihydromyricetin extracted from Ampelopsis grossedentata leaves", published in International Journal of Pharmaceutics, Volume 511, Issue 1, 10 September 2016, pages 245-252, mentioned that dihydromyricetin products may contain a dihydromyricetin racemate due to racemization during extraction, crystallization, high-temperature exposure and / or metal contact. Wang et al. subsequently set out to achieve extraction of homochiral pure (+)dihydromyricetin. Umair et al. concluded that studied (-) dihydromyricetin had a strong potential as synthetic antioxidant or antimicrobial agent in food or phytopharmaceuticals, but did not consider cosmetics, such as for example a skincare cream or a haircare lotion.

[0013]

[0010] Li et al. in their article titled “Study on the stability of molecular chirality and the configuration protection of dihydromyricetin in vine tea", published in Food Science & Nutrition, 2024, vol. 89, pages 3569-3576, mentions the impact of four key factors, namely, temperature, water source, metal ion, and pH, on the stability of molecular chirality of dihydromyricetin (DMY). Li et al refer to the racemization process of DMY and mention the 4 theoretical stereoisomers. However, also Li et al do not refer to any use in cosmetics.

[0014]

[0011] Lin et al. in their article titled “Semi-preparative separation of dihydromyricetin enantiomers by supercritical fluid chromatography and determination of anti-inflammatory activities”, published in the Journal of Chromatography, 2019, vol. 1606, item 460386, refer to the development of a supercritical fluid chromatography approach for chiral separation of dihydromyricetin. However, also Lin et al do not refer to any use in cosmetics.

[0015]

[0012] Amongst others in view of its epigenetic activity, dihydromyricetin is a compound of increasing interest for cosmetics. It would therefore be an advancement in the art to increase potency and / or lower the undesired degradation effects associated with conventional dihydromyricetin.

[0016] SUMMARY OF THE INVENTION

[0017]

[0013] Inventors have now surprisingly found that by using the other stereoisomers of (2R,3R)-dihydromyricetin in non-therapeutic, non-food applications, such as cosmetic preparations, potency may advantageously be increased. This increased potency in turn advantageously allows for lower dosages to be applied, which subsequently may advantageously result in less undesired degradation symptoms such as unpleasant odor- and color changes of a product formulation.

[0018]

[0014] Accordingly, the invention provides in a first aspect a method of application, preferably a method of cosmetic and / or topical application, of one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin to a keratinous material, preferably skin and / or hair.

[0019]

[0015] In a preferred embodiment the non-therapeutic, non-food preparation, preferably cosmetic preparation, comprises (2R,3R)-dihydromyricetin enriched with one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin, more preferably it comprises (2R,3R)-dihydromyricetin enriched with (2R,3S)-dihydromyricetin.

[0020]

[0016] In a second aspect, the invention provides a use of one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin as a cosmetic ingredient, preferably as an active cosmetic agent. That is, the invention provides one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin for use in a non-therapeutic, non-food preparation, preferably a cosmetic preparation. More preferably, the invention provides the use of one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin as an epigenetic active agent and / or as a senolytic active agent, for example for cosmetic or dermatological skin care.

[0021]

[0017] In a third aspect, the invention provides a non-therapeutic, non-food preparation, preferably a cosmetic preparation, comprising one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin. More preferably, the invention provides a non-therapeutic, non-food preparation, preferably a cosmetic preparation, comprising (2R,3S)-dihydromyricetin.

[0022]

[0018] In a fourth aspect, the invention provides a process for the preparation of dihydromyricetin enriched in one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin comprising the steps of

[0023] (a) providing (2R, 3R)-dihydromyricetin;

[0024] (b) converting the (2R, 3R)-dihydromyricetin in a mixture of dihydromyricetin stereoisomers comprising

[0025] - (2R, 3R)-dihydromyricetin, and

[0026] - one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin; and

[0027] (c) preferably increasing the concentration of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin in the mixture of dihydromyricetin stereoisomers.

[0028] In the above method, preferably step (c) is carried out with the help of physical and / or chemical processes, more preferably with the help of chiral chromatography.

[0029]

[0019] Advantageously some of the dihydromyricetin stereoisomers were purified and created in an isolated form for the first time. Hence in a fifth aspect, the invention provides an isolated and / or purified (2S,3R)-dihydromyricetin compound. That is, in a fifth aspect the invention provides a dihydromyricetin compound (also referred to herein as simply “dihydromyricetin”) comprising:

[0030] - equal to or more than 80 mol. %, more preferably equal to or more than 90 mol. % , even more preferably equal to or more than 95 mol. % and most preferably equal to or more than 99 mol. % of (2S,3R)-dihydromyricetin isomer; and

[0031] - equal to or less than 20 mol. %, more preferably equal to or less than 10 mol. % , even more preferably equal to or less than 5 mol. % and most preferably equal to or less than 1 mol. % of (2R,3R)-dihydromyricetin isomer.The invention preferably provides a (2S,3R)-dihydromyricetin compound with a purity of equal to or more than 90 % w / w, more preferably equal to or more than 95 % w / w, most preferably equal to or more than 99 % w / w, based on the total weight of the dihydromyricetin stereoisomers present.

[0032]

[0020] As illustrated by the examples, the above composition, use, method, process and compound advantageously allows for higher potency, more preferably for a more prominent epigenetic activity, and thereby allows one to use lower dosages and have less undesired degradation side-effects.

[0033] DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS

[0034]

[0021] Unless defined otherwise or clearly indicated by context, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0035]

[0022] The articles “a” and “an” are used herein to refer to one or to more than one (i.e. to one or at least one) of the grammatical object of the article. By way of example, “an element” may mean one element or more than one element. When referring to a noun (e.g. a compound, an additive, etc.) in the singular, the plural is meant to be included. Thus, when referring to a specific moiety, e.g. a "compound", this means "at least one" of that compound, e.g. "at least one compound", unless specified otherwise.

[0036]

[0023] Throughout the present specification and the accompanying claims, all transitional phrases such as ‘comprising,’ ‘including,’ ‘carrying,’ ‘having,’ ‘containing,’ ‘involving,’ ‘holding,’ ‘composed of’, and variations such as "comprises", "comprise", "includes" and "include" are to be interpreted inclusively and to be understood to be open-ended, i.e., to mean including but not limited to. That is, these words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows. Only the transitional phrases ‘consisting of’ and ‘consisting essentially of’ shall be closed or semi-closed transitional phrases, respectively.

[0037]

[0024] The term 'consisting essentially of as used herein means that the total amount of the listed ingredients ideally sums up to 100 wt. % (weight percent). It is however not excluded that small amount of impurities derived from the ingredients and / or the production process may be present.

[0025] Throughout this application, the term "about" is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

[0038]

[0026] As used herein, the terms “% by weight”, “wt. %”, “weight percentage”, or “percentage by weight” are used interchangeably. The same applies mutatis mutandis to the terms “% by volume”, “vol. %”, “vol. percentage”, or “percentage by volume”, respectively to the terms “% by mol”, “mol %”, “mol percentage”, or “percentage by mol”.

[0039]

[0027] Unless explicitly indicated otherwise, the various embodiments of the invention described herein can be cross-combined. That is, each alternative and / or embodiment so defined herein may be combined with any other alternative and / or embodiment herein, and this for each variant unless clearly indicated to the contrary or clearly incompatible when the value range of a same parameter is disjoined. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

[0040]

[0028] The terms “cosmetic product”, "cosmetic composition " and “cosmetic preparation” are used interchangeably herein and refer in the present document to a composition suitable for cosmetic purposes. The terms can be used interchangeably. Suitably a cosmetic composition is herein understood to be a composition for cosmetic, that is, non-therapeutic use. More preferably the terms “cosmetic product”, "cosmetic composition " and “cosmetic preparation” refer in the present document to a composition which is applied to the surface of a mammalian keratinous tissue. Such composition can be understood to be the so-called finished product, to be delivered to the customer. The terms “cosmetic product", "cosmetic composition " and “cosmetic preparation” can comprise or consist of those cosmetic compositions as defined under the heading "Kosmetika" in Rdmpp Lexikon Chemie, 10th edition 1997, Georg Thieme Verlag Stuttgart, New York as well as to cosmetic compositions as disclosed in A. Domsch, "Cosmetic Compositions", Verlag fur chemische Industrie (ed. H. Ziolkowsky), 4thedition, 1992. More preferably the "cosmetic composition " or “cosmetic preparation” is a cosmetic preparation, respectively a cosmetic composition, that can be topically applied to mammalian keratinous tissue such as e.g. human skin, scalp or hair (including eyelashes, the eyebrows, the nails or the lips). Hence, the cosmetic composition is preferably a topical composition. By a topical composition isherein understood a composition for, preferably external, use on keratinous tissue such as the skin, scalp or hair.

[0041]

[0029] The term “keratinous tissue" as used in this document refers to tissue containing keratine, more preferably it means the skin (including the scalp), head hair, eyelashes, eyebrows, bodily hairs, nails and / or lips. Preferably, the keratinous tissue is the skin, scalp or hair.

[0042]

[0030] The terms “carrier”, “carrier component” and “carrier ingredient” are used interchangeably herein. The term “carrier” is preferably understood to refer to an ingredient in a composition that can serve as a medium to deliver an active ingredient and / or other ingredients to an intended site of action. Preferably such a carrier may help to stabilize, distribute, and / orfacilitate the application of such an active ingredient. The carrier is preferably a cosmetically acceptable carrier. By a cosmetically acceptable carrier is herein preferably understood a carrier that is accepted for cosmetic purposes. More preferably the carrier is a carrier suitable for topical application to a keratinous tissue, preferably having good aesthetic properties, preferably compatible with the actives present in the composition, and / or preferably the carrier will not cause any unreasonable safety or toxicity concerns. Such carriers are well-known to one of ordinary skill in the art and can include one or more compatible liquid(s) or solid filler diluent(s), excipient(s), additive(s) or vehicle(s) which are suitable for application to skin, scalp and / or hair.

[0043]

[0031] The terms “active ingredient”, “active agent” and simply “agent” or “active” are used interchangeably herein. These terms preferably refer to a substance or ingredient that has a specific physiological or biochemical effect on a keratinous tissue such as the skin, scalp or hair. Such agents may suitably be included in a composition, preferably a cosmetic composition, for their ability to target and address specific concerns or provide benefits, such as for example moisturizing, anti-aging, brightening, soothing, or protecting. Active agents can thus advantageously be key ingredients responsible for the claimed efficacy of a cosmetic composition.

[0044]

[0032] The terms “helper ingredient”, “helper component” and “excipient” are used interchangeably herein. These terms preferably refer to a substance or ingredient used in a composition to serve as an aid in the processing, stability, and / or delivery of the active ingredients. Excipients can for example be used to ensure the proper form, consistency, and / or stability of a product. Examples of the functions of excipients thusinclude stabilizing, binding, filling, preserving, facilitating thereof and / or aiding in the delivery of active ingredients. Preferred examples of excipients include stabilizers and / or preservatives.

[0045]

[0033] The terms “ingredient pre-mix” and “ingredient pre-mix formulation” are used interchangeably herein. By an “ingredient pre-mix”, respectively an “ingredient pre-mix formulation”, is herein preferably understood a combination a specific ingredient, such as a cosmetically active ingredient, with one or two other ingredients to allow it to be supplied by the ingredient manufacturer to the producer of a certain product, such as a cosmetic product. The producer of the cosmetic product may combine the “ingredient pre-mix” with multiple other ingredients to prepare a cosmetic product. Preferably the ingredient pre-mix is a cosmetic ingredient pre-mix, that is an ingredient pre-mix wherein the ingredient is a cosmetically acceptable ingredient.

[0046]

[0034] By the term “stereoisomers” is herein preferably understood two or more compounds which have the same molecular formula and the same connectivity of atoms (that is, the same structural formula), but which differ in the three-dimensional arrangement of their atoms in space. This spatial difference can lead to distinct physical and chemical properties, even though the atoms are bonded in the same order. More preferably, the term “stereoisomers” is herein understood to refer to two or more compounds which have the same molecular formula and the same connectivity of atoms, but which are not superimposable. The term stereoisomers is herein preferably understood to include both enantiomers (non-superimposable mirror images) and diastereomers (not mirror images).

[0047]

[0035] By the terms “enriched”, “enrichment” and ’’enriching” is herein preferably understood the selectively increasing of a certain ingredient through a physical or chemical process. That is, when a mixture is enriched with a certain substance, that substance becomes more abundant than it was before. For example in the present invention, the dihydromyricetin in the claimed preparations may preferably become more enriched with certain stereoisomers following one or more physical and / or chemical steps to induce isomerization. In the current context, wherein the 2R,3R dihydromyricetin stereoisomer is the original, naturally occurring stereoisomer, enriching is preferably achieved by:

[0048] - converting an 2R,3R dihydromyricetin stereoisomer, into one or more of the 2R,3S dihydromyricetin stereoisomer, 2S,3R dihydromyricetin stereoisomer and / or 2S,3Sdihydromyncetin stereoisomer, preferably by at least 5 mol. %, more preferably by at least 10 mol %, based on the total moles of original 2R,3R dihydromyricetin stereoisomer, through physical or chemical processes; and / or

[0049] - adding one or more of previously isolated 2R,3S dihydromyricetin stereoisomer, 2S,3R dihydromyricetin stereoisomer and / or 2S,3S dihydromyricetin stereoisomer to original 2R,3R dihydromyricetin stereoisomer, at quantities leading to at least 5 mol. %, more preferably by at least 10 mol %, based on the total moles of original 2R,3R dihydromyricetin stereoisomer, of one or more of the 2R,3S dihydromyricetin stereoisomer, 2S,3R dihydromyricetin stereoisomer and / or 2S,3S dihydromyricetin stereoisomer in the final blend.

[0050] DIHYDROMYRICETIN

[0051]

[0036] Dihydromyricetin (herein also abbreviated as “DHM”) is a hexahydroxyflavan-4-one having the structural formula (I)

[0052]

[0053] OH O (|)

[0054]

[0037] As explained above, dihydromyricetin comprises two chiral atoms (also referred to herein as stereocenters or chirality centers) and there exist four theoretical stereoisomers of dihydromyricetin, (2R,3R)-dihydromyricetin (also referred to as (+) dihydromyricetin), (2S,3S)-dihydromyricetin (also referred to as (-) dihydromyricetin), (2R,3S)-dihydromyricetin and (2S,3R)-dihydromyricetin.

[0055]

[0038] The stereoisomers are herein below illustrated with the respective structural formulae (IA), (IB), (IC) and (ID).

[0056] OH

[0057]

[0058] OH O (|A)Formula (IA) shows the (2R,3R)-dihydromyricetin stereoisomer, herein also referred to as simply “(2R,3R)-dihydromyricetin”

[0059] OH

[0060]

[0061] OH O (|B)

[0062] Formula (IB) shows the (2S,3S)-dihydromyricetin stereoisomer, herein also referred to as simply “(2S,3S)-dihydromyricetin”

[0063]

[0064] Formula (IC) shows the (2R,3S)-dihydromyricetin stereoisomer, herein also referred to as simply “(2R,3S)-dihydromyricetin”

[0065] OH

[0066]

[0067] OH O (|D)

[0068] Formula (ID) shows the (2S,3R)-dihydromyricetin stereoisomer, herein also referred to as simply “(2S,3R)-dihydromyricetin”

[0069]

[0039] In a preferred embodiment the non-therapeutic, non-food preparation, preferably cosmetic preparation, comprises (2R,3R)-dihydromyricetin enriched withone or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin.

[0070]

[0040] That is, in a preferred embodiment the non-therapeutic, non-food preparation, preferably cosmetic preparation, comprises dihydromyricetin, wherein such dihydromyricetin comprises or consists of a blend (herein also referred to as a “mixture”) of (2R,3R)-dihydromyricetin stereoisomer with one or more stereoisomers selected from the group consisting of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and (2S,3R)-dihydromyricetin.

[0071]

[0041] The (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin can advantageously be derived from the (2R,3R)-dihydromyricetin stereoisomer, for example by isomerization as described herein below and illustrated in the examples.

[0072]

[0042] In all aspects of the invention, such (2R,3R)-dihydromyricetin stereoisomer may be chemically or microbiologically produced and / or may be derived or obtained from a natural source. More preferably the (2R,3R)-dihydromyricetin stereoisomer is obtained or derived from a natural source, for example by means of extraction, more preferably solvent extraction. Examples of natural sources from which the (2R,3R)-dihydromyricetin stereoisomer can be extracted include Hovenia species such as Hovenia dulcis (also referred to as the Oriental raisin tree); Ampelopsis species such as Ampelopsis japonica, Ampelopsis megalophylla, and Ampelopsis grossedentata Cercidiphyllum species such as Cercidiphyllum japonicunr, Rhododendron species such as Rhododendron cinnabarinunr, some Pinus species; Cedrus species, such as Cedrus deodara, Salix species such as Salix sachalinensis ; as well as some Pinaceae. Of these, Hovenia dulcis and Ampelopsis grossedentata are preferred natural sources. The (2R,3R)-dihydromyricetin stereoisomer may conveniently be obtained or derived from the stems and / or leaves of such natural sources.

[0073]

[0043] The (2R,3R)-dihydromyricetin stereoisomer can also be commercially obtained.

[0074]

[0044] In all embodiments of this invention, the (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin stereoisomers may be chemically or microbiologically produced and / or may be derived or obtained, for example via physical and or chemical processes, from a natural source.

[0045] More preferably the (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin stereoisomers are prepared or obtained by converting the, preferably naturally derived, (2R, 3R)-dihydromyricetin stereoisomer, preferably via physical or chemical processes, into such (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin stereoisomer(s) and preferably subsequently isolating such, for example as described in more detail below.

[0075]

[0046] The invention therefore also advantageously provides dihydromyricetin, more preferably a blend of dihydromyricetin stereoisomers, comprising, based on the total amount of moles of dihydromyricetin,

[0076] - equal to or more than 1 mol. %, more preferably equal to or more than 5 mol. %, even more preferably equal to or more than 10 mol. %, still more preferably equal to or more than 20 mol. %, and most preferably equal to or more than 30 mol. %, and suitably equal to or less than 100 mol. %, more suitably equal to or less than 99 mol. %, of one or more stereoisomers chosen from the group consisting of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin stereoisomer(s), more preferably equal to or more than 1 mol. %, more preferably equal to or more than 5 mol. %, even more preferably equal to or more than 10 mol. %, still more preferably equal to or more than 20 mol. %, and most preferably equal to or more than 30 mol. %, and suitably equal to or less than 100 mol. %, more suitably equal to or less than 99 mol. %, of (2R,3S)-dihydromyricetin stereoisomer,

[0077] - wherein any balance may be any other dihydromyricetin stereoisomers.

[0078]

[0047] The invention also advantageously provides dihydromyricetin, more preferably a blend of dihydromyricetin stereoisomers, comprising, based on the total amount of moles of dihydromyricetin,

[0079] - equal to or more than 50 mol. %, more preferably equal to or more than 70 mol. %, even more preferably equal to or more than 80 mol. %, still more preferably equal to or more than 90 mol. %, yet more preferably equal to or more than 95 mol. %, and most preferably equal to or more than 99 mol. %, and suitably equal to or less than 100 mol. %, of one or more stereoisomers chosen from the group consisting of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin stereoisomer(s), more preferably equal to or more than 50 mol. %, more preferably equal to or more than 70 mol. %, even more preferably equal to or more than 80 mol. %, still more preferably equal to or more than 90 mol. %, yet more preferably equal toor more than 95 mol. %, and most preferably equal to or more than 99 mol. %, and suitably equal to or less than 100 mol. %, of (2R,3S)-dihydromyricetin stereoisomer, - wherein any balance may be any other dihydromyricetin stereoisomers.

[0080]

[0048] The invention further advantageously provides dihydromyricetin, more preferably a blend of dihydromyricetin stereoisomers, comprising, based on the total amount of moles of dihydromyricetin,

[0081] - equal to or more than 1 mol. %, more preferably equal to or more than 5 mol. %, even more preferably equal to or more than 10 mol. %, still more preferably equal to or more than 20 mol. %, and most preferably equal to or more than 30 mol. %, and suitably equal to or less than 100 mol. %, more suitably equal to or less than 99 mol. %, of one or more stereoisomers chosen from the group consisting of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin stereoisomer(s), more preferably equal to or more than 1 mol. %, more preferably equal to or more than 5 mol. %, even more preferably equal to or more than 10 mol. %, still more preferably equal to or more than 20 mol. %, and most preferably equal to or more than 30 mol. %, and suitably equal to or less than 100 mol. %, more suitably equal to or less than 99 mol. %, of (2R,3S)-dihydromyricetin stereoisomer; and - equal to or less than 99 mol. %, preferably equal to or less than 95 mol. %, more preferably equal to or less than 90 mol. % , even more preferably equal to or less than 80 mol. % and most preferably equal to or less than 70 mol. %, and suitably equal to or more than 0 mol. %, more suitably equal to or more than 1 mol. %, of (2R,3R)-dihydromyricetin isomer.

[0082]

[0049] The invention further advantageously provides dihydromyricetin, more preferably a blend of dihydromyricetin stereoisomers, comprising, based on the total amount of moles of dihydromyricetin,

[0083] - equal to or more than 50 mol. %, more preferably equal to or more than 70 mol. %, even more preferably equal to or more than 80 mol. %, still more preferably equal to or more than 90 mol. %, yet more preferably equal to or more than 95 mol. %, and most preferably equal to or more than 99 mol. %, and suitably equal to or less than 100 mol. %, of one or more stereoisomers chosen from the group consisting of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin stereoisomer(s), more preferably equal to or more than 50 mol. %, more preferably equal to or more than 70 mol. %, even more preferably equal to or more than 80 mol.%, still more preferably equal to or more than 90 mol. %, yet more preferably equal to or more than 95 mol. %, and most preferably equal to or more than 99 mol. %, and suitably equal to or less than 100 mol. %, of (2R,3S)-dihydromyricetin stereoisomer; and

[0084] - equal to or less than 50 mol. %, more preferably equal to or less than 30 mol. % , even more preferably equal to or less than 20 mol. %, still more preferably equal to or less than 10 mol. %, yet more preferably equal to or less than 5 mol. %, and most preferably equal to or less than 1 mol. %, and suitably equal to or more than 0 mol. %, of (2R,3R)-dihydromyricetin isomer.

[0085]

[0050] The above blends of dihydromyricetin stereoisomers, may advantageously be applied in all aspects of the invention.

[0086]

[0051] In another preferred embodiment the invention provides a non-therapeutic, non-food preparation, preferably a cosmetic preparation, comprising dihydromyricetin, wherein such dihydromyricetin comprises or consists of one or more of (2S,3S)-dihydromyricetin stereoisomer, (2R,3S)-dihydromyricetin stereoisomer and / or (2S,3R)-dihydromyricetin stereoisomer, wherein preferably the composition comprises no or essentially no (2R,3R)-dihydromyricetin.

[0087] NON-THERAPEUTIC, NON-FOOD PREPARATION

[0088]

[0052] The invention provides in a third aspect a non-therapeutic, non-food preparation, preferably a cosmetic preparation, preferably comprising one or more of a (2S,3S)-dihydromyricetin stereoisomer, a (2R,3S)-dihydromyricetin stereoisomer and / or a (2S,3R)-dihydromyricetin stereoisomer.

[0089]

[0053] The non-therapeutic, non-food preparation is preferably a topical composition (also referred to herein as a “topical preparation”).

[0090]

[0054] The invention therefore also provides a cosmetic composition, more preferably a topical cosmetic composition, a cosmetic preparation, comprising one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin and preferably further comprising a cosmetically acceptable carrier such as glycerin.

[0091]

[0055] As indicated above, such a preparation may or may not comprise an additional (2R,3R)-dihydromyricetin stereoisomer.

[0092]

[0056] That is, in one preferred embodiment the non-therapeutic, non-food preparation, preferably cosmetic preparation, comprises dihydromyricetin, whereinsuch dihydromyricetin comprises or consists of a blend (also referred to herein as a “mixture”) of:

[0093] - a (2R,3R)-dihydromyricetin stereoisomer; and

[0094] - one or more stereoisomers selected from the group consisting of (2S,3S)-dihydromyricetin stereoisomer, (2R,3S)-dihydromyricetin stereoisomer and (2S,3R)-dihydromyricetin stereoisomer.

[0095]

[0057] For example, the non-therapeutic, non-food preparation, preferably a cosmetic preparation, may advantageously comprise (2R,3R)-dihydromyricetin in combination with (2S,3S)-dihydromyricetin, (2R,3R)-dihydromyricetin in combination with (2R,3S)-dihydromyricetin and / or (2R,3R)-dihydromyricetin in combination with (2S,3R)-dihydromyricetin. Further preferences are as described above. Preferences for blends of dihydromyricetin stereoisomers are as described above.

[0096]

[0058] Preferably the non-therapeutic, non-food preparation is a preparation wherein the preparation comprises (2R,3R)-dihydromyricetin in a molar ratio of moles (2R,3R)-dihydromyricetin to total moles (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin of equal to or less than 50 : 1, preferably equal to or less than 20 : 1, more preferably equal to or less than 10 : 1, most preferably equal to or less than 5 : 1.

[0097]

[0059] More preferably the non-therapeutic, non-food preparation is a preparation wherein the preparation comprises (2R,3R)-dihydromyricetin in a molar ratio of moles (2R,3R)-dihydromyricetin to moles (2R,3S)-dihydromyricetin of equal to or less than 50 : 1, preferably equal to or less than 20 : 1, more preferably equal to or less than 10 : 1 , most preferably equal to or less than 5 : 1.

[0098]

[0060] Preferably the non-therapeutic, non-food preparation comprises a blend of dihydromyricetin stereoisomers. Further preferences for such a blend are as described above.

[0099]

[0061] In another preferred embodiment the invention provides a non-therapeutic, non-food preparation, preferably a cosmetic preparation, comprising dihydromyricetin, wherein such dihydromyricetin comprises or consists of one or more of (2S,3S)-dihydromyricetin stereoisomer, (2R,3S)-dihydromyricetin stereoisomer and / or (2S,3R)-dihydromyricetin stereoisomer, wherein preferably the composition comprises no or essentially no (2R,3R)-dihydromyricetin.

[0062] Preferably the non-therapeutic, non-food preparation, preferably a cosmetic preparation, comprises an amount of dihydromyricetin in the range from equal to or more than 0.001 wt. %, more preferably from equal to or more than 0.01 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 1 wt. %, based on the total weight of the preparation.

[0100]

[0063] More preferably the preparation is a cosmetic preparation, preferably comprising a total amount of one or more of a (2S,3S)-dihydromyricetin stereoisomer, a (2R,3S)-dihydromyricetin stereoisomer and / or a (2S,3R)-dihydromyricetin stereoisomer in the range from equal to or more than 0.001 wt. %, more preferably from equal to or more than 0.005 wt. %, even more preferably from equal to or more than 0.01 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 1 wt. %, based on the total weight of the preparation.

[0101]

[0064] Preferably the non-therapeutic, non-food preparation is a cosmetic preparation. Such cosmetic preparation is herein below also referred to as a “cosmetic composition” or as “cosmetic product”.

[0102]

[0065] The dihydromyricetin compounds can be used as a solution, a dispersion, an emulsion or encapsulated in carriers such as macro-, micro- or nanocapsules, in liposomes or chylomicrons, or enclosed in macro-, micro- or nanoparticles or in microsponges or absorbed on powdered organic polymers, talc, bentonite and further inorganic carriers.

[0103]

[0066] Preferably, the dihydromyricetin compounds are either incorporated as such or in the form of a solution (blend) comprising the compounds according to the present invention into cosmetic compositions. Particularly suitable solutions are for examples the ones formed with a polyalcohol, such as e.g. glycerin, butylene glycol and propylene glycol and the like. Such solutions can be prepared according to standard procedures in the art. Such solutions may further contain water and further stabilizers and / or additives.

[0104]

[0067] The term “cosmetic preparation” preferably refers to compositions which are used to treat, care for or improve the appearance of skin (including the scalp) and / or hair. Particular advantageous cosmetic compositions are skin care compositions.

[0105]

[0068] The compositions according to the invention are preferably intended for topical application, which is to be understood as the external application to keratinoussubstances, such as in particular the skin and even more in particular the face. That is, preferably the non-therapeutic, non-food preparation is a topical composition.

[0106]

[0069] Preferably the non-therapeutic, non-food preparation, preferably a cosmetic preparation, is a skin care composition, a sun care composition or a haircare composition. Most preferably the topical composition is a skin care composition. As explained below, suitably the non-therapeutic, non-food preparation, preferably cosmetic preparation, can be applied in a variety of forms including for example as a gel, cream, ointment, lotion, serum, powder, spray, mask or two component dispensing system. Preferably the topical composition is applied in a spreadable form. Hence, preferably the non-therapeutic, non-food preparation, preferably a cosmetic preparation, is not applied in the form of a patch or a plaster. That is, preferably the non-therapeutic, non-food preparation, is not, and is not part of, a patch or a plaster.

[0107]

[0070] As explained herein above and herein below, the preparation may comprise the dihydromyricetin as an active ingredient. In accordance with the present invention, the preparation according to the invention may also comprise further active ingredients conventionally used in topical, preferably cosmetic, preparations. Preferred additional active ingredients include: skin lightening agents, UV-filters, agents for the treatment of hyperpigmentation, agents for the prevention or reduction of inflammation, firming, moisturizing, soothing, and / or energizing agents as well as agents to improve elasticity and skin barrier.

[0108]

[0071] Preferably the preparation comprises one or more UV filters. Preferred UV filters include Titanium Dioxide, Zinc Oxide, Benzophenone-3 (also referred to as Oxybenzone), Benzophenone-4 (also referred to as Sulisobenzone), Benzophenone-5, Butyl Methoxydibenzoylmethane (also referred to as Avobenzone), Ethylhexyl Methoxycinnamate (also referred to as Octinoxate), Ethylhexyl Salicylate (also referred to as Octisalate), Homosalate, Octocrylene, Terephthalylidene Dicamphor Sulfonic Acid, Drometrizole Trisiloxane, Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine (also referred to as Bemotrizinol or “BEMT”), Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (also referred to as Bisoctrizole, “MBBT”” ), Diethylamino Hydroxybenzoyl Hexyl Benzoate (also referred to as “DHHB”), Ethylhexyl Triazone (also referred to as “EHT”), Polysilicone-15, Isoamyl p-Methoxycinnamate, Phenylbenzimidazole Sulfonic Acid, Bisdisulizole Disodium, Tris-Biphenyl Triazine and / or combinations of one or more of these. Of these, homosalate, octocrylene,ethylhexyl salicylate, bis-ethylhexyloxyphenol methoxyphenyl triazine, butyl methoxydibenzoylmethane, Ethylhexyl triazone , Tris-biphenyl triazine and mixtures thereof are especially preferred.

[0109]

[0072] Preferably the preparation comprises hyaluronic acid and / or a derivative thereof. More preferably the preparation comprises hyaluronic acid, a hyaluronate salt, (such as for example sodium hyaluronate), hydrolyzed hyaluronic acid, cross-linked hyaluronic acid or any combination of one or more of these.

[0110]

[0073] In a preferred embodiment, the preparation may preferably further comprise one or more vitamins or derivatives thereof selected from the group consisting of retionoids / carotene, preferably retinol (vitamin A), thiamin (vitamin B1), riboflavin (vitamin B2), niacin and / or niacinamide (vitamin B3), pantothenic acid (vitamin B5), pyridoxine (vitamin B6), cobalamin (vitamin B12), biotin, ascorbic acid (vitamin C), choline, calciferol (vitamin D), alpha-tocopherol (vitamin E), folic acid (vitamin B9), phylloquinone (vitamin K) and / or any combination thereof.

[0111]

[0074] In a preferred embodiment, the preparation may preferably further comprise bakuchiol.

[0112]

[0075] In a preferred embodiment, the preparation may preferably further comprise -for example as a senolytic agent - myricitrin and / or Epilobrium fleicheri extract.

[0113]

[0076] Conveniently the preparation may comprise one or more further ingredients, also referred to herein as helper ingredients (excipients), including one or more carriers. More preferably the preparation further comprises a carrier, Preferences for such ingredients are as described above and below.

[0114]

[0077] Preferably the carrier is a cosmetically acceptable carrier. Preferred carriers include water and oils. Most preferably the carrier comprises water and / or glycerol.

[0115]

[0078] The composition according to the present invention can have a wide variety of forms. Non limiting examples include simple solutions (e.g. aqueous, organic solvent, or oil based), emulsion or micro emulsion (in particular of oil-in-water (O / W) or water-in-oil (W / O) type, silicone-in-water (Si / W) or water-in-silicone (W / Si) type, PIT-emulsion, multiple emulsion (e.g. of oil-in-water-in oil (O / W / O) or water-in-oil-in-water (W / O / W) type) or pickering emulsions), as well as solid forms (e.g. hydrogels, alcoholic gels, lipogels, sticks, flowable solids, or amorphous materials). These forms may be used for a number of applications, including, but not limited to, gels, creams,ointments, lotions, serums, powder, aerosol sprays or two component dispensing systems.

[0116]

[0079] In a preferred embodiment, the compositions according to the present invention are emulsions and / or gels. Even more preferably, the compositions are emulsions which contain an oily phase and an aqueous phase such as in particular O / W, W / O, Si / W, W / Si, O / W / O, W / O / W multiple or a pickering emulsions.

[0117]

[0080] Preferably, the preparation comprises a solution, dispersion or emulsion comprising the dihydromyricetin and a non-aqueous liquid. Preferably such nonaqueous liquid comprises:

[0118] - an oil or fat, such as for example almond oil, castor oil, coconut oil, groundnut oil, jojoba oil, olive oil, palm oil, rapeseed oil, soybean oil, sunflower oil, or a triglyceride, such as a capric or caprylic acid triglyceride, or any combination of one or more of these; and / or

[0119] - an alcohol, diol, or polyol, preferably ethanol, isopropanol, ethylene glycol, propylene glycol, glycerol, or an ether or ester thereof, most preferably glycerol; and / or

[0120] - any combination of the above.

[0121]

[0081] In addition, the preparation preferably comprises a solution, dispersion or emulsion comprising an aqueous liquid. Preferably such aqueous liquid comprises: - water; and / or

[0122] - one or more surfactants; and / or

[0123] - one of more buffering ingredients such as an acid or a base.

[0124]

[0082] The topical compositions of the invention (including the carrier) may comprise further conventional (cosmetic) excipients, such as preservatives / antioxidants, fatty substances / oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, antifoaming agents, aesthetic components such as fragrances, aroma ingredients, surfactants, fillers, anionic, cationic, non-ionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colourings / colorants, abrasives, absorbents, chelating agents and / or sequestering agents, essential oils, skin sensates, astringents, pigments or any other ingredients suitable for inclusion into such compositions.

[0125]

[0083] Of course, one skilled in this art will take care to select the above mentioned optional additional ingredients, adjuvants, diluents and additives and / or their amounts such that the advantageous properties intrinsically associated with the combination inaccordance with the invention are not, or not substantially, detrimentally affected by the envisaged addition or additions.

[0126]

[0084] The topical compositions according to the present invention can advantageously be cosmetic skin care compositions, cosmetic sun care compositions and / or cosmetic hair care compositions. Preferred examples of such skin care compositions include creams, serums, exfoliating scrubs, masks, lotions, gels, sprays and balms.

[0127]

[0085] Hence preferred examples of the preparations according to the invention include skincare compositions, such as a hydrating lotion or a cream, such as a facecare cream; and / or haircare compositions such as hair masks, hair lotions or shampoos.

[0128]

[0086] The topical composition can advantageously be a leave-on or rinse-off composition, preferably a leave-on composition.

[0129]

[0087] In a preferred embodiment the composition according to the inventions can be sold or advertised or otherwise named as an epigenetic composition, anti-aging composition or anti-aging product.

[0130]

[0088] In a special preferred embodiment the invention provides a cosmetic preparation, more preferably a topical cosmetic composition, comprising one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin, which composition further comprises one or more ingredients chosen from the group consisting of:

[0131] glycerin, water, cocoglycerides, caprylic / capric triglyceride, octyldodecanol, glyceryl stearate, cetearyl alcohol, starch, Butyrospermum parkii butter, cetyl palmitate, squalane, hyaluronic acid and / or a salt thereof such as sodium hyaluronate, sodium stearoyl glutamate, ethyl hexylglycerin, xanthan gum, trisodium EDTA, sodium hydroxide, citric acid, diethylhexyl syringylidenemalonate, sodium metabisulphite, phenoxyethanol and citronellol.

[0132]

[0089] The preferences as described above are also applicable for other aspects of this invention such as the below described method where such a preparation (also sometimes referred to herein as composition) may be applied to a keratinous material such as skin or hair.USE AND METHOD OF APPLICATION

[0133]

[0090] In a first aspect, the invention provides a method of application, preferably a method of cosmetic and / or topical application, of one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin to a keratinous material, preferably skin and / or hair.

[0134]

[0091] Preferences for blends are as described above.

[0135]

[0092] Preferably the dihydromyricetin is applied to the skin in an amount effective to prevent DNA-methylation, more preferably in an amount in the range from equal to or more than 0.001 wt. %, more preferably from equal to or more than 0.01 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 1 wt. %, based on the total weight of the topical composition.

[0136]

[0093] In the method above, preferably the one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin are comprised in a cosmetic preparation, where the preferences for such a cosmetic preparation are as described in the section above. Preferably such a cosmetic preparation is a topical cosmetic preparation.

[0137]

[0094] More preferably, in the method above, the one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin are comprised in a composition, preferably a cosmetic composition, most preferably a topical cosmetic composition, which composition further comprises one or more ingredients chosen from the group consisting of:

[0138] glycerin, water, cocoglycerides, caprylic / capric triglyceride, octyldodecanol, glyceryl stearate, cetearyl alcohol, starch, Butyrospermum parkii butter, cetyl palmitate, squalane, hyaluronic acid and / or a salt thereof such as sodium hyaluronate, sodium stearoyl glutamate, ethyl hexylglycerin, xanthan gum, trisodium EDTA, sodium hydroxide, citric acid, diethylhexyl syringylidenemalonate, sodium metabisulphite, phenoxyethanol and citronellol.

[0139]

[0095] In a second aspect, the invention provides a use of one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin as a cosmetic ingredient, preferably as an active cosmetic agent. For example the (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin may be applied as an anti-aging active agent, an anti-cellulite active agent, an epigenetic active agent or a senolytic active agent. More preferably, the invention provides theuse of one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin as an anticellulite active agent, an anti-aging active agent, an epigenetic active agent and / or as a senolytic active agent, for example for cosmetic or dermatological skin care. That is, the invention also provides one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin for use as an anti-aging active agent, an epigenetic active agent and / or as a senolytic active agent, for example in a cosmetic or dermatological skin care preparation.

[0140]

[0096] Preferences for blends are as described above.

[0141]

[0097] Preferably the use concentration of the dihydromyricetin in all aspects of the invention, whether in the stereoisomers are present in a pure form or whether a blend of dihydromyricetin stereoisomers is applied, may preferably lie in the range from equal to or more than 0.01 wt. % to equal to or less than 2 wt. % in a final consumer product, mor preferably in the range from equal to or more than 0.05 wt. % to equal to or less than 1 wt. %, based on the total weight of the product applied.

[0142] PROCESS FOR PREPARATION

[0143]

[0098] In a fourth aspect, the invention provides a process for the preparation of dihydromyricetin enriched in one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin comprising the steps of

[0144] (a) providing (2R, 3R)-dihydromyricetin;

[0145] (b) converting the (2R, 3R)-dihydromyricetin in a mixture of dihydromyricetin stereoisomers comprising

[0146] - (2R, 3R)-dihydromyricetin, and

[0147] - one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin; and

[0148] (c) preferably increasing the concentration of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin in the mixture of dihydromyricetin stereoisomers.

[0149]

[0099] The (2R, 3R)-dihydromyricetin stereoisomer is commercially available as pure substance or for example as Hovenia Dulcis Extract. Step (a) may conveniently comprise the extraction of (2R, 3R)-dihydromyricetin from one or more natural sources as described above. Such extraction may conveniently be carried out by means of the chelating extraction method as described by Hu et al, in their article titled “New Methodfor Extracting and Purifying Dihydromyricetin from Ampelopsis grossedentata” published in ACS Omega, 2020, vol. 5, pages 13955-13962, incorporated herein by reference.

[0150] Step (b) may conveniently be carried out by solving the (2R, 3R)-dihydromyricetin stereoisomer in a suitable solvent, preferably water, at a suitable temperature, preferably in the range from 10°C to 60°C, more preferably in the range from 15°C to 30°C, most preferably in the range from 20°C to 25°C. An example of how such a step can be carried out is provided in example 1 below. Suitably step (b) yields a blend of dihydromyricetin stereoisomers as described herein before.

[0151]

[0100] In the above method, preferably step (c) is carried out with the help of chiral chromatography. Preferably step (c), more preferably such chiral chromatography, comprises contacting the mixture of dihydromyricetin stereoisomers with a chiral environment, preferably a chiral stationary phase (CSP).

[0152]

[0101] Such chiral chromatography can for example be performed by means of high-performance liquid chromatography (HPLC), gas chromatography (GC), and supercritical fluid chromatography (SFC).

[0153]

[0102] By means of the above method, preferably an dihydromyricetin is prepared that is enriched in 2R,3S dihydromyricetin stereoisomer, 2S,3R dihydromyricetin stereoisomer and / or 2S,3S dihydromyricetin stereoisomer. That is the dihydromyricetin may preferably become more enriched with such stereoisomers following one or more physical and / or chemical steps to induce isomerization.

[0154]

[0103] The present invention therefore also provides an enrichment process wherein, starting from the 2R,3R dihydromyricetin stereoisomer, preferably enriching is achieved, by including in such process the steps of:

[0155] - converting the 2R,3R dihydromyricetin stereoisomer, into one or more of the 2R,3S dihydromyricetin stereoisomer, 2S,3R dihydromyricetin stereoisomer and / or 2S,3S dihydromyricetin stereoisomer, preferably by at least 5 mol. %, more preferably by at least 10 mol %, based on the total moles of the 2R,3R dihydromyricetin stereoisomer before conversion, through physical or chemical processes; and / or

[0156] - adding one or more of previously isolated 2R,3S dihydromyricetin stereoisomer, 2S,3R dihydromyricetin stereoisomer and / or 2S,3S dihydromyricetin stereoisomer to the 2R,3R dihydromyricetin stereoisomer, at quantities leading to at least 5 mol. %, more preferably by at least 10 mol % of one or more of the 2R,3S dihydromyricetinstereoisomer, 2S,3R dihydromyricetin stereoisomer and / or 2S,3S dihydromyricetin stereoisomer, based on the total moles of the 2R,3R dihydromyricetin stereoisomer before the addition.

[0157] In the below the invention has been illustrated by the following non-limiting examples.

[0158] EXAMPLES

[0159] Example 1. Preparation of (2R, 3S) and / or (2S,3R)-Dihydromyricetin

[0160]

[0104] Commercially obtained (2R, 3R)-Dihydromyricetin was dissolved in water (1 mg / mL) and stirred at 20-25 °C for 24 h. The isomers were separated by chromatography using a HSS T3 column (acetonitrile / water, 2% acetonitrile - 7 min -15% - 5 min - 100% acetonitrile). Retention time of (2R, 3R)-isomer: 6.5 min, (2S, 3R)-isomer: 7.3 min. The sum amount of the (2R, 3S)- and / or (2S, 3R) isomer is approximately 10%.

[0161] Example 2. In silico efficacy of various dihydromyricetin isomers versus comparison ((2R,3R)-DHM)

[0162]

[0105] Four stereoisomers of dihydromyricetin (DHM) were docked into the cofactor binding site of DNA(cytosine-5)-methyltransferase 1 (DNMT1) using the Glide docking program and a crystal structure from the Protein Data Bank (accession code 4WXX). As validation, the binding mode of the cocrystallized cofactor was predicted in silico and showed a root mean-square deviation of 0.37 A indicating optimal predictive power of the model. The predicted binding affinities of the isomers are given in Table 1 where lower values indicate stronger inhibition of the enzyme. The data indicates that the (R,R)-isomer shows weakest inhibition.Table 1: in silico predicted binding affinities of the isomers

[0163] Isomer Affinity (kcal / mol)

[0164] (2S,3S)- dihydromyricetin -5.699

[0165] (2S,3R)- dihydromyricetin -5.631

[0166] (2R,3S)- dihydromyricetin -5.334

[0167] (2R,3R)- dihydromyricetin -5.086

[0168]

[0169]

[0106] The results illustrate that the stereoisomers (2R,3S)-dihydromyricetin, (2S,3R)-dihydromyricetin and (2S,3S)-dihydromyricetin have an improved inhibitory effect on DNA methyltransferase 1 ((DNMT1) and are therefore predicted to have improved epigenetic and other activities.

[0170] Example 3 : Exemplified formulations

[0171] Please find below exemplified formulations comprising mixtures of dihydromyricetin stereoisomers as indicated in the tables below. Formulation 1 is an Aqueous solution. Formulations 2 are Oil-in-Water (O / W) formulations. Formulations 3 are O / W formulations.Formulation 1 : Aqueous solution 1 AQUA Ad 100 PROPANEDIOL 3.00 PENTYLENE GLYCOL 3.00 GLYCERIN 1.00 CAPRYLYL GLYCOL 0.20 GLYCERIN, AQUA, CITRIC ACID, SCUTELLARIA ALPINA 3.00 FLOWER / LEAF / STEM EXTRACT

[0172] SACCHARIDE ISOMERATE, AQUA, CITRIC ACID, SODIUM 1.00 CITRATE AQUA, SODIUM HYDROXIDE 0.30 PROPANEDIOL 39.50 ASCORBIC ACID 3.16 PALMITOYL TRIPEPTIDE-5, GLYCERIN, AQUA 3.00 (2R,3S)-DIHYDROMYRICETIN ISOMER 0.05 DIHYDROMYRICETIN STEREOISOMERS OTHER THAN 0.10 (2R,3S)-DIHYDROMYRICETIN

[0173] ISOAMYL LAURATE 23.80 ARGANIA SPINOSA KERNEL OIL 3.00 HIPPOPHAE RHAMNOIDES OIL 0.24 PROPANEDIOL DICAPRYLATE 13.55 PASSIFLORA INCARNATASEED OIL 10.00 TOCOPHEROL 0.50 PARFUM, LINALOOL, LIMONENE, CITRUS LIMON PEEL OIL, 0.25 CITRUS AURANTIUM BERGAMIA PEEL OIL, HYDROXYCITRONELLAL, LINALYL ACETATE, CITRONELLOL, CITRUS AURANTIUM PEEL OIL, PINENE, TERPINEOL, TETRAMETHYL ACETYLOCTAHYDRONAPHTHALENES

[0174]

[0175] 1 2 3 4 5 6 7 8 9 10 11 Formulations 2 (O / W Daycare creams)

[0176] 3-O-ETHYLASCORBIC ACID 2

[0177] 20

[0178] Acetyl Hexapeptide-8

[0179] ppm ACRYLATES / C10-30ALKYLACRYLATE

[0180] 0.15 0.25 CROSSPOLYMER

[0181] Add Add Add Add Add Add Add Add Add Add Add AQUA

[0182] 100 100 100 100 100 100 100 100 100 100 100 ASCORBIC ACID 2

[0183] ASCORBYL GLUCOSIDE 2

[0184] bentonite

[0185] BUTYLENE GLYCOL 2 2 2 2 2 2

[0186] C12-15 Alkylbenzoate 3

[0187] Camellia Sinensis Leaf Extract 0.5 1 CAPRYLIC / CAPRIC TRIGLYCERIDE 10 3 6 Carrageenan 0.1

[0188] CETEARYL ALCOHOL 0.6 CETEARYL GLUCOSIDE 3 CETEARYL ISONONANOATE 2 2 2 2 2 2

[0189] CETYLALCOHOL 1.5 1.5 1.5 1.5 1.5 1.5 2

[0190]

[0191] CITRIC ACID qs qs qs qs qs qs 0.2 0.2 DICAPRYLYL ETHER 4 4 4 4 4 4 2

[0192] DISODIUM EDTA 0.1 0.1 0.1 0.1 0.1 0.1 0.1

[0193] DMDM Hydantoin 0.2 0.2 EDTA 0.2

[0194] ETHYL ASCORBIC ACID 2

[0195] Ethylhexylcoco fatty acid esters 2

[0196] Filling agents / Additives 0.5

[0197] GLYCERIN 4 3 3 3 3 3 3 5 4 5 3 Glyceryl Glucoside 2 2.5 GLYCERYL MYRISTATE 1.5 1.5 1.5 1.5 1.5 1.5

[0198] GLYCERYL STEARATE 0.8

[0199] Glyceryl isostearate 3 2 Glyceryl stearate citrate 2

[0200] Helianthus Annuus (Sunflower) Seed Oil 2 Hydrogenated Coco Glyceride 2.5 1

[0201] lsoceteth-20 5 3 ISOPROPYL PALMITATE 3 LEONTOPODIUM ALPINUM EXTRACT 2.5

[0202]

[0203] MAGNESIUM ASCORBYL PHOSPHATE 2

[0204] Methyl Methacrylate Crosspolymer 2 Methylpropandiol

[0205] MINERAL OIL 2 5 4 Natriumcitrate 0.4 0.4 Mixture of dihydromyricetin stereoisomers 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 including (2R,3R)-dihydromyricetin and TO TO TO TO TO TO TO TO TO TO TO (2R,3S)-dihydromyricetin 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% NIACINAMIDE 5

[0206] PANTHENOL.AQUA 0.5

[0207] Parabene 0.4

[0208] Perfume q.s. q.s. q.s. Phenoxyethanol 0.4 0.4 PHENOXYETHANOL,

[0209] ETHYLHEXYLGLYCERIN POTASSIUM HYDROXIDE, AQUA 0.7

[0210] Potassium Sorbate 0.15 PROPANEDIOL 1 1 1 1 1 1

[0211] PRUNUSAMYGDALUS DULCIS OIL 1.5 Rosa Gallica Flower Extract 5

[0212]

[0213] SCLEROTIUM GUM 0.2 0.2 0.2 0.2 0.2 0.2

[0214] SODIUM ASCORBYL PHOSPHATE 2 2 0.1

[0215] Sodium Benzoate 0.25 SODIUM HYDROXIDE qs qs qs qs qs qs 0.3 SODIUM METABISULFITE 0.05 0.05 0.02 0.01 0.02 0.03

[0216] SORBITAN STEARATE, SUCROSE

[0217] 2.5

[0218] COCOATE STEARETH-2 1.5 1.5 1.5 1.5 1.5 1.5

[0219] STEARETH-21 1.5 1.5 1.5 1.5 1.5 1.5

[0220] Stearylalcohol 2

[0221] TOCOPHEROL 0.1 Tocopherylacetate 0.5 0.4 Ubiquinone (Coenzym Q10) 0.1

[0222] Water and / or oil soluble dyes 0.05 XANTHANGUM 0.7 0.3 0.3 0.3 0.3 0.3 0.3 0.2

[0223]

[0224] Formulations 3 1 2 3 (O / W Hydrating Face Lotion)

[0225] Mixture of dihydromyricetin stereoisomers 0.2 0.2 0.2 including (2R,3R)-dihydromyricetin and

[0226] (2R,3S)-dihydromyricetin

[0227] Sodium Hyaluronate 0.2 0.2 0.3 Octyldodecanol 2 0 0 Isopropyl Palmitate 0 0 6 Dibutyl Adipate 2 0 0 Cetearyl Isononanoate 0 1 0 Glyceryl Stearate Citrate 2 2 1 Glyceryl Stearate 1 1 1.5 Cetearyl Alcohol 1 1 1 Parfum 0.5 0 0 Glycerin 5 5 5 Butylene Glycol 5 5 5 Phenoxyethanol 0.4 0.6 0.6 Alcohol Denat. 6 4 4 Ethylhexylglycerin 0.2 0.1 0.15 Trisodium EDTA 0 0 0 Trisodium Ethylenediamine Disuccinate 1 1 0.5 Xanthan Gum 0.1 0.1 0.2 Succinoglycan 0.1 0.1 0.1 Gellan Gum 0.05 0.1 0.1 Sodium Metabisulfite 0.05 0.1 0.2 Diethylhexyl Syringylidenemalonate 0.15 0.15 0.05 ad 100 ad 100 ad 100

[0228]

[0229] Aqua (to 100)

Claims

CLAIMS1. A method of application of one or more of (2S,3S)-dihydromyricetin, (2R,3S)- dihydromyricetin and / or (2S,3R)-dihydromyricetin to a keratinous material, preferably skin and / or hair.

2. The method according to claim 1 , wherein the one or more of (2S,3S)- dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin are comprised in a composition, which composition further comprises one or more ingredients chosen from the group consisting of:glycerin, water, cocoglycerides, , caprylic / caprictriglyceride, octyldodecanol, glyceryl stearate, cetearylalcohol, starch, Butyrospermum parkii butter, cetylpalmitate, squalane, hyaluronic acid and / or a salt thereof such as sodium hyaluronate, sodium stearoyl glutamate, ethylhexylglycerin, xanthangum, trisodium EDTA, sodium hydroxide, citric acid, diethylhexyl syringylidenemalonate, sodium metabisulphite, phenoxyethanol and citronellol.

3. The method according to claim 2, wherein such composition is a topical composition.

4. A use of one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin as a cosmetic ingredient, preferably as an active cosmetic agent, more preferably as an epigenetic active agent and / or as a senolytic active, most preferably for cosmetic or dermatological skin care.

5. A use of a blend of dihydromyricetin stereoisomers, comprising, based on the total amount of moles of dihydromyricetin,- equal to or more than 1 mol. %, more preferably equal to or more than 5 mol. %, even more preferably equal to or more than 10 mol. %, still more preferably equal to or more than 20 mol. %, and most preferably equal to or more than 30 mol. %, and suitably equal to or less than 100 mol. %, more suitably equal to or less than 99 mol. %, of one or more stereoisomers chosen from the group consisting of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)- dihydromyricetin stereoisomer(s), more preferably equal to or more than 1 mol. %, more preferably equal to or more than 5 mol. %, even more preferably equal to or more than 10 mol. %, still more preferably equal to or more than 20 mol. %, and most preferably equal to or more than 30 mol. %, and suitably equal to or less than 100 mol. %, more suitably equal to or less than 99 mol. %, of (2R,3S)- dihydromyricetin stereoisomer,- wherein any balance may be any other dihydromyricetin stereoisomers, as a cosmetic ingredient, preferably as an active cosmetic agent, more preferably as an epigenetic active agent and / or as a senolytic active, most preferably for cosmetic or dermatological skin care.

6. The use according to claim 4 or 5, wherein the dihydromyricetin is applied to the skin in an amount effective to prevent DNA-methylation.

7. A non-therapeutic, non-food preparation, preferably a cosmetic preparation, comprising one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin.

8. The non-therapeutic, non-food preparation according to claim 7, wherein the preparation is a topical composition9. The non-therapeutic, non-food preparation according to any one of claims 7 to 8, wherein the preparation further comprises (2R,3R)-dihydromyricetin in a molarratio of moles (2R,3R)-dihydromyricetin to total moles of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin of equal to or less than 50 : 1, preferably equal to or less than 20 : 1, more preferably equal to or less than 10 : 1, most preferably equal to or less than 5 : 1.

10. The non-therapeutic, non-food preparation according to any one of claims 7 to 9, wherein the preparation comprises a blend of dihydromyricetin stereoisomers, comprising, based on the total amount of moles of dihydromyricetin,- equal to or more than 1 mol. %, more preferably equal to or more than 5 mol. %, even more preferably equal to or more than 10 mol. %, still more preferably equal to or more than 20 mol. %, and most preferably equal to or more than 30 mol. %, and suitably equal to or less than 100 mol. %, more suitably equal to or less than 99 mol. %, of one or more stereoisomers chosen from the group consisting of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)- dihydromyricetin stereoisomer(s), more preferably equal to or more than 1 mol. %, more preferably equal to or more than 5 mol. %, even more preferably equal to or more than 10 mol. %, still more preferably equal to or more than 20 mol. %, and most preferably equal to or more than 30 mol. %, and suitably equal to or less than 100 mol. %, more suitably equal to or less than 99 mol. %, of (2R,3S)- dihydromyricetin stereoisomer,- wherein any balance may be any other dihydromyricetin stereoisomers.

11. The non-therapeutic, non-food preparation according to any one of claims 7 to 10, wherein the preparation comprises dihydromyricetin in an amount in the range from equal to or more than 0.001 wt. %, more preferably from equal to or more than 0.01 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 1 wt. %, based on the total weight of the preparation.

12. The non-therapeutic, non-food preparation according to any one of claims 7 to 11 , wherein the topical composition further comprises one or more UV filters; and / or hyaluronic acid or a derivative thereof.

13. A process for the preparation of dihydromyricetin enriched in one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)- dihydromyricetin comprising the steps of(a) providing (2R, 3R)-dihydromyricetin;(b) converting the (2R, 3R)-dihydromyricetin in a mixture of dihydromyricetin stereoisomers comprising- (2R, 3R)-dihydromyricetin, and- one or more of (2S,3S)-dihydromyricetin, (2R,3S)-dihydromyricetin and / or (2S,3R)-dihydromyricetin; and(c) preferably increasing the concentration of (2S,3S)-dihydromyricetin, (2R,3S)- dihydromyricetin and / or (2S,3R)-dihydromyricetin in the mixture of dihydromyricetin stereoisomers.

14. The process according to claim 13 , wherein step (b) is carried out by means of a physical or chemical process.

15. A (2S,3R)-dihydromyricetin compound having a purity of equal to or more than 90 % w / w, more preferably equal to or more than 95 % w / w, most preferably equal to or more than 99 % w / w, based on the total weight of dihydromyricetin present.